Cal-Maine
CALM
$73.71
+0.66%
Cal-Maine Foods Inc is the largest producer and distributor of fresh shell eggs in the United States, offering a diverse portfolio that includes conventional, specialty, cage-free, nutritionally enhanced, organic, brown, pasture-raised, and free-range eggs to retail and foodservice customers nationwide. As the dominant player in the U.S. egg market, Cal-Maine's scale and vertical integration provide a competitive edge in a commodity-driven industry. The current investor narrative centers on the company's strategic expansion through acquisitions like Creighton Brothers, which strengthens its Midwest footprint, while the stock faces headwinds from declining egg prices and a challenging demand environment following a period of avian flu-driven price spikes. Recent earnings beat expectations, signaling a return to market stability, but the steep year-over-year revenue decline has kept investors cautious about the sustainability of earnings.…
CALM
Cal-Maine
$73.71
Related headlines
Investment Opinion: Should I buy CALM Today?
Rating: Hold. The stock is fairly valued given the cyclical downturn, with a forward PE of 20.82x near the industry average of 22x. The average analyst target of $88 implies 17.9% upside, but limited coverage and neutral ratings suggest no strong conviction. The thesis is that Cal-Maine's dominant market position and strong balance sheet will allow it to weather the current price slump, but earnings normalization will limit near-term upside.
Sign up to view all
CALM 12-Month Price Forecast
The AI assessment is neutral with medium confidence. Cal-Maine's strong balance sheet and market leadership are offset by the sharp revenue decline and expected earnings normalization. The stock appears fairly valued at current levels, with the forward PE near the industry average. Upside is limited unless egg prices recover faster than expected, while downside is cushioned by the low trailing PE and dividend yield. A shift to bullish would require evidence of stabilizing egg prices and upward earnings revisions, while a further deterioration in prices or a dividend cut would warrant a bearish stance.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cal-Maine's 12-month outlook, with a consensus price target around $84.00 and implied upside of +14.0% versus the current price.
Average Target
$84.00
0 analysts
Implied Upside
+14.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$79 - $90
Analyst target range
Analyst coverage is limited, with only 4 analysts providing targets, and the consensus recommendation is 'none' (likely reflecting a lack of strong buy/sell conviction). The average target price is $88.00, implying an upside of 17.9% from the current price of $74.63. The distribution of ratings is not explicitly provided, but the recent actions from firms like Stephens & Co. (Equal Weight) and BMO Capital (Market Perform) suggest a neutral stance, with no recent upgrades or downgrades. The low target of $79.00 and high target of $100.00 indicate a relatively wide spread of $21, reflecting uncertainty about the future path of egg prices and the company's earnings power. The high target of $100 assumes a recovery in egg prices and successful integration of acquisitions, while the low target of $79 suggests continued price weakness and margin compression. Given the limited coverage and neutral ratings, investors may need to rely on their own analysis of the egg market cycle to assess Cal-Maine's prospects.
Bulls vs Bears: CALM Investment Factors
Cal-Maine presents a classic cyclical value trap versus a genuine bargain. The bull case rests on its dominant market position, pristine balance sheet, and low trailing PE, while the bear case highlights the severe revenue decline, expected earnings normalization, and negative momentum. Currently, the bearish evidence is stronger given the steep downtrend and forward PE near industry average, suggesting the market has already priced in a return to normal earnings. The key tension is whether egg prices have bottomed and can stabilize, which would validate the low trailing PE and support a recovery, or if further declines will erode earnings and push the stock below its 52-week low. Resolution of this price cycle is the single most important factor for the investment thesis.
Bullish
- Dominant Market Position: Cal-Maine is the largest U.S. shell egg producer, with a market cap of $3.56B and a diverse portfolio including conventional, specialty, cage-free, and organic eggs. This scale provides pricing power and distribution advantages that smaller competitors lack, supporting long-term market share stability.
- Strong Balance Sheet: The company has zero debt (debt-to-equity of 0) and a current ratio of 7.70, indicating ample liquidity to weather cyclical downturns. This financial strength enables strategic acquisitions like Creighton Brothers, which expands its Midwest footprint and scale.
- Attractive Trailing Valuation: With a trailing PE of 11.24x versus the industry average of 22x, the stock trades at a 49% discount. This low multiple reflects the cyclical earnings peak, but for value investors, it offers a margin of safety if earnings normalize above current estimates.
- High Dividend Yield: The dividend yield is 6.51%, supported by a payout ratio of 73%. This provides a substantial income component, which is attractive in a low-yield environment and cushions total return potential even if price appreciation is limited.
Bearish
- Sharp Revenue Decline: Q3 FY2026 revenue fell 52.95% YoY to $667M from $1.42B, reflecting the collapse in egg prices after the avian flu-driven spike. Sequential declines from $922.6M in Q1 to $667M in Q3 indicate a rapid normalization that may continue.
- Earnings Normalization Expected: The forward PE of 20.82x versus trailing 11.24x implies the market expects EPS to drop from $6.64 to $4.76, a 28% decline. This suggests that current profitability is unsustainable and will revert to historical norms.
- Negative Price Momentum: The stock is down 34% over the past year and 12.9% in the last month, underperforming the S&P 500 by 52.6 percentage points. The price sits near the 52-week low of $71.92, indicating persistent selling pressure and weak technicals.
- Limited Analyst Conviction: With only 4 analysts and a consensus recommendation of 'none', institutional sentiment is neutral at best. The average target of $88 implies just 17.9% upside, and the low target of $79 is only 5.9% above the current price, reflecting high uncertainty.
CALM Technical Analysis
Cal-Maine's stock is in a clear downtrend, with a 1-year price change of -34.0%, significantly underperforming the S&P 500's +18.65% gain over the same period. The current price of $74.63 sits near the lower end of its 52-week range, at approximately 65% of the range (calculated as (74.63 - 71.92) / (115.49 - 71.92)), indicating the stock is closer to its 52-week low of $71.92 than its high of $115.49. This positioning suggests a market that has priced in significant pessimism, potentially offering value if fundamentals stabilize, but also reflecting a persistent downtrend that could continue if support levels fail.
Beta
0.21
0.21x market volatility
Max Drawdown
-38.0%
Largest decline past year
52-Week Range
$72-$112
Price range past year
Annual Return
-32.7%
Cumulative gain past year
| Period | CALM Return | S&P 500 |
|---|---|---|
| 1m | -10.7% | -1.6% |
| 3m | -5.6% | +2.2% |
| 6m | -16.1% | +14.4% |
| 1y | -32.7% | +16.2% |
| ytd | -6.1% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CALM Fundamental Analysis
Cal-Maine's revenue trajectory has been highly volatile, with the most recent quarter (Q3 FY2026, ending February 28, 2026) reporting revenue of $667 million, a steep 52.95% decline year-over-year from $1.42 billion in the prior-year quarter. This decline follows a period of exceptionally high egg prices driven by avian flu outbreaks, which inflated revenues in fiscal 2025. The sequential trend shows a clear deceleration: Q1 FY2026 revenue was $922.6 million, Q2 was $769.5 million, and Q3 fell to $667 million, indicating a sharp normalization in egg prices. The company's revenue segments reveal that non-specialty shell eggs dominate, contributing $1.02 billion (approximately 72% of total), while specialty eggs contributed $328.9 million, and egg products and other made up the remainder. The investment case hinges on whether the company can maintain profitability as prices normalize, with the recent acquisition of Creighton Brothers expected to expand scale and geographic reach.
Quarterly Revenue
$666951000.0B
2026-02
Revenue YoY Growth
-52.9%
YoY Comparison
Gross Margin
17.9%
Latest Quarter
Free Cash Flow
$722862000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CALM Overvalued?
Given that Cal-Maine is profitable (net income of $50.5 million in the most recent quarter), the PE ratio is the appropriate primary valuation metric. The trailing PE is 11.24x, while the forward PE is 20.82x, indicating that the market expects earnings to decline significantly from current levels, as the forward PE is based on estimated EPS of $4.76 versus trailing EPS of approximately $6.64 (calculated from net income of $504.6 million and shares outstanding of 47.3 million). The gap between trailing and forward PE suggests the market is pricing in a normalization of earnings after an exceptionally profitable period, which is consistent with the revenue decline. Compared to the industry average PE of 22x (based on available data), Cal-Maine's trailing PE of 11.24x represents a 49% discount, but the forward PE of 20.82x is close to the industry average, implying that the market expects earnings to revert to more normalized levels. Historically, Cal-Maine's PE has ranged from as low as 2.17x in Q3 FY2025 to over 596x in Q1 FY2024, reflecting the extreme cyclicality of egg prices. The current trailing PE of 11.24x is in the middle of this historical range, suggesting that the market is not pricing in either extreme optimism or pessimism, but rather a moderate expectation of earnings normalization.
PE
11.2x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 2x~20x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
7.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant due to the extreme cyclicality of egg prices. Revenue in Q3 FY2026 fell 52.95% YoY, and sequential declines from $922.6M to $667M indicate a rapid normalization that could continue if prices remain weak. The company's net margin of 10.88% is down from over 30% in the prior year, and the forward PE of 20.82x implies expected EPS of $4.76, a 28% decline from trailing EPS of $6.64. While the balance sheet is strong with zero debt and a current ratio of 7.70, the reliance on a single commodity exposes earnings to supply shocks, such as avian flu, which can cause both spikes and crashes in prices. The high payout ratio of 73% could pressure the dividend if earnings fall further, though the company's cash reserves provide a buffer.
FAQ
The primary risk is the cyclicality of egg prices, which caused a 52.95% YoY revenue decline in Q3 FY2026. If prices continue to fall, earnings could miss estimates, and the stock could drop below its 52-week low of $71.92. A second risk is the high payout ratio of 73%, which could force a dividend cut if earnings deteriorate further, reducing the stock's income appeal. Third, the limited analyst coverage (only 4 analysts) and neutral ratings provide little support, and the stock has underperformed the market by 52.6 percentage points over the past year, indicating negative momentum. Finally, competitive pressures from alternative proteins and potential regulatory changes in cage-free mandates could impact demand and costs. The most severe risk is a prolonged downturn in egg prices, which could lead to a 20% or more decline from the current price.
The 12-month forecast for Cal-Maine is uncertain, with a base case probability of 50% for a price range of $75-$88, aligning with the average analyst target of $88. The bull case, with a 25% probability, targets $88-$100, assuming a recovery in egg prices and successful acquisitions. The bear case, also 25% probability, targets $65-$75, if egg prices decline further. The most likely scenario is the base case, where egg prices stabilize and the stock trades in a range, with limited upside. The key assumption is that egg prices have bottomed and will not fall significantly below current levels. Investors should monitor quarterly earnings and egg price trends to adjust their expectations.
Cal-Maine's trailing PE of 11.24x is 49% below the industry average of 22x, suggesting the stock is undervalued based on past earnings. However, the forward PE of 20.82x is close to the industry average, indicating that the market expects earnings to normalize to about $4.76 per share. This implies the stock is fairly valued when considering forward earnings. The stock's historical PE range is extremely wide, from 2.17x to 596x, reflecting the cyclicality of egg prices. The current valuation suggests the market is pricing in a moderate decline in earnings, not a collapse, which seems reasonable given the recent revenue trends. Investors should focus on the forward PE and the sustainability of egg prices rather than the trailing multiple.
Cal-Maine is a good buy for investors with a high risk tolerance and a long-term horizon, given its cyclical nature. The stock offers a 17.9% upside to the average analyst target of $88, but the low target of $79 is only 5.9% above the current price, indicating significant downside risk. The trailing PE of 11.24x is attractive, but the forward PE of 20.82x suggests earnings will decline, making the stock fairly valued. The key is whether egg prices have bottomed; if they have, the stock could be a bargain, but if they fall further, it could drop to the 52-week low of $71.92 or below. For conservative investors, waiting for a clearer bottom in egg prices may be prudent.
Cal-Maine is better suited for long-term investment, given its cyclical nature and the need to wait for the egg price cycle to turn. The stock has a beta of 0.225, indicating low volatility relative to the market, but its earnings are highly volatile, making short-term trading risky. The dividend yield of 6.51% provides income while waiting for a recovery, but the payout ratio of 73% could be cut if earnings fall. For long-term investors, a minimum holding period of 3-5 years is recommended to ride out the cycle and benefit from the company's market leadership and acquisitions. Short-term traders may find opportunities in the wide price swings, but the negative momentum and limited analyst support make it a challenging trade. The company's zero debt and strong cash position support its ability to survive downturns, making it a viable long-term hold for those who can tolerate volatility.